drugset
drugset / Trial / NCT01749891

A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration

NCT01749891 ↗

Phase 1/2 Completed 25 enrolled Allegro Ophthalmics, LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The general objective of this study is to evaluate the safety and efficacy of ophthalmic intravitreal injections of ALG-1001 in human subjects with wet age-related macular degeneration (Wet AMD). This study builds upon the safety and efficacy results of numerous animal studies and an earlier Phase I Human Study in end-stage diabetic macular edema patients.

Timeline

Start
2012-03
Primary completion
2013-06-04
Completion
2013-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Risuteganib Protein / enzyme biologic 1.5 mg Intravitreal
Subject Risuteganib Protein / enzyme biologic 2.5 mg Intravitreal
Subject Risuteganib Protein / enzyme biologic 4 mg Intravitreal

Indications

macular degeneration